Cite
Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab
MLA
Kyrtsonis, Maria-Christina Siakantaris, Marina P.Kalpadakis, Christina Dimopoulou, Maria N.Vassilakopoulos, Theodoros P.and Kontopidou, Flora N.Antoniou, Christina Korkolopoulou, Penelope and Panayiotidis, Panayiotis Pangalis, Gerassimos A. Favorable Outcome of Primary Cutaneous Marginal Zone Lymphoma Treated with Intralesional Rituximab. Jan. 2006. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..0da07e42434d0d90bb22c2ba460e1f77&authtype=sso&custid=ns315887.
APA
Kyrtsonis, M.-C. S. M. P. K. C. D. M. N. V. T. P. and K. F. N. A. C. K. P. and P. P. P. G. A. (2006). Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab.
Chicago
Kyrtsonis, Maria-Christina Siakantaris, Marina P. Kalpadakis, Christina Dimopoulou, Maria N. Vassilakopoulos, Theodoros P. and Kontopidou, Flora N. Antoniou, Christina Korkolopoulou, Penelope and Panayiotidis, Panayiotis Pangalis, Gerassimos A. 2006. “Favorable Outcome of Primary Cutaneous Marginal Zone Lymphoma Treated with Intralesional Rituximab,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.od......2127..0da07e42434d0d90bb22c2ba460e1f77&authtype=sso&custid=ns315887.